Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
09
Today In Oncology
Considerations on Cancer Drug Development
Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
PD-1 Inhibitor Approved for Adjuvant Treatment of CSCC
Systemic Anticancer Therapy at End of Life and Health-Care Use Among Older Patients
Inotuzumab Ozogamicin Followed by Blinatumomab in Older Patients With Newly Diagnosed B-Cell ALL
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo